Initiator Pharma announced today that it has signed a screening agreement with the National Institute on Drug Abuse (NIDA) to evaluate the pharmacology of preclinical candidates IPDP2015 and IPNP2015. Nida’s addiction Treatment Discovery Program will study the candidates' potential as treatments for stimulant addiction, specifically their effects on cocaine- and methamphetamine-related behavior.